Recent Company News

• 08:21 PM ET Aug 24, 2025
  

  Hutchmed CEO Weiguo Su to take leave of absence due to health reasons (HK$25.40, 0.00)

• 08:07 PM ET Aug 19, 2025
  

  Hutchmed completes patient enrollment for Phase III Trial of ORPATHYS and TAGRISSO as first-line therapy for certain NSCLC patients in China (HK$25.90, 0.00)

• 08:35 PM ET Aug 12, 2025
  

  Hutchmed downgraded to overweight from buy at Soochow Securities (12-Aug, timing uncertain) (HK$24.06, 0.00)

• 11:54 PM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:06 PM ET Jul 28, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:00 AM ET Aug 07, 2025
  

  StreetAccount Metrics Recap - Hutchmed H1 Earnings (HK$28.02, 0.00)

• 07:20 AM ET Aug 07, 2025
  

  Hutchmed reports H1 EPS $0.52 vs FactSet $0.29 [3 est, $0.02-0.56] (HK$28.02, 0.00)

• 03:06 AM ET Aug 03, 2025
  

  StreetAccount Consensus Metrics Preview - Hutchmed H1 Earnings (HK$27.30, 0.00)

• 05:48 AM ET Aug 01, 2025
  

  StreetAccount Sector Summary - China Healthcare July Recap